Delving into the Latest Updates on ReNeuron Ltd. with Synapse

概览

排名前五的药物类型	数量

外泌体药物	3
干细胞疗法	1

关联

6

项与 ReNeuron Ltd. 相关的药物

Human retinal progenitor cells (ReNeuron Ltd.)

靶点-

作用机制

干细胞替代物

在研机构

ReNeuron Ltd.

原研机构

ReNeuron Group Plc

在研适应症

视网膜色素变性

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

Exo-miR(ReNeuron)

靶点-

作用机制-

在研机构

ReNeuron Ltd.

原研机构

ReNeuron Ltd.

在研适应症-

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

ReN-009

靶点-

作用机制

细胞替代物

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

8

项与 ReNeuron Ltd. 相关的临床试验

NCT05598775 / Enrolling by invitationN/A

Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

The purpose of this long-term safety study is to follow up subjects treated with CTX0E03 DP to monitor for delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival

开始日期2022-11-01

申办/合作机构

ReNeuron Ltd.

NCT03629275 / Terminated临床2期

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

A study of stereotactic, intracerebral injection of CTX0E03 neural stem cells into patients with moderate to moderately severe disability as a result of an ischemic stroke.

开始日期2018-08-31

申办/合作机构

ReNeuron Ltd.

NCT03333980 / CompletedN/A

A Non-interventional Observational Clinical Study to Document the Clinical Course of Patients 12 Months or More Following an Ischaemic Stroke

A non-interventional observational clinical study to document the clinical course of patients at 12 months or more following an ischaemic stroke

开始日期2017-05-01

申办/合作机构

ReNeuron Ltd.

100 项与 ReNeuron Ltd. 相关的临床结果

登录后查看更多信息

0 项与 ReNeuron Ltd. 相关的专利（医药）

登录后查看更多信息

22

项与 ReNeuron Ltd. 相关的文献（医药）

2023-08-01·Cytotherapy

A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, "Therapeutic advances with native and engineered human extracellular vesicles".

Article

作者: Toh, Wei Seong ; Herz, Josephine ; Williams, Douglas ; Lim, Sai Kiang ; Weiss, Daniel J ; De Fougerolles, Antonin ; Gimona, Mario ; Cho, Byong Seung ; Khoury, Maroun ; Yarani, Reza ; Corteling, Randolph ; Rohde, Eva ; Giebel, Bernd ; El Andaloussi, Samir ; Robbins, Paul D ; Choi, Chulhee

The International Society for Cell & Gene Therapy Scientific Signature Series event "Therapeutic Advances With Native and Engineered Human EVs" took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.

2020-04-01·Journal of Neurology, Neurosurgery & Psychiatry1区 · 医学

Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2)

1区 · 医学

Article

作者: Willmot, Mark ; Sprigg, Nikola ; Stroemer, Paul ; Ward, Nick ; Majid, Arshad ; Howell, Julian ; Pollock, Kenneth ; Dixit, Anand ; Dunn, Laurence ; Bath, Philip ; Tyrrell, Pippa ; Bulters, Diederik ; Muir, Keith W ; Sinden, John

BackgroundHuman neural stem cell implantation may offer improved recovery from stroke. We investigated the feasibility of intracerebral implantation of the allogeneic human neural stem cell line CTX0E03 in the subacute—chronic recovery phase of stroke and potential measures of therapeutic response in a multicentre study.MethodsWe undertook a prospective, multicentre, single-arm, open-label study in adults aged >40 years with significant upper limb motor deficits 2–13 months after ischaemic stroke. 20 million cells were implanted by stereotaxic injection to the putamen ipsilateral to the cerebral infarct. The primary outcome was improvement by 2 or more points on the Action Research Arm Test (ARAT) subtest 2 at 3 months after implantation.FindingsTwenty-three patients underwent cell implantation at eight UK hospitals a median of 7 months after stroke. One of 23 participants improved by the prespecified ARAT subtest level at 3 months, and three participants at 6 and 12 months. Improvement in ARAT was seen only in those with residual upper limb movement at baseline. Transient procedural adverse effects were seen, but no cell-related adverse events occurred up to 12 months of follow-up. Two deaths were unrelated to trial procedures.InterpretationAdministration of human neural stem cells by intracerebral implantation is feasible in a multicentre study. Improvements in upper limb function occurred at 3, 6 and 12 months, but not in those with absent upper limb movement at baseline, suggesting a possible target population for future controlled trials.FundingReNeuron, Innovate UK (application no 32074-222145).Trial registration numberEudraCT Number: 2012-003482-18

2019-08-01·Journal of Neurology, Neurosurgery & Psychiatry

Increased deep grey matter functional connectivity of poststroke hNSC implanted ipsilesional putamen

Letter

作者: Kalladka, Dheeraj ; Moreton, Fiona Catherine ; McLean, John ; Muir, Keith W ; Sinden, John ; Huang, Xuya

Although stroke results in focal brain tissue loss, remote effects consequent to the disruption of structural and functional networks are recognised. Resting-state functional connectivity MRI has the ability to image subjects with a broad range of impairments following stroke without the interpretive confound of variable task performance seen in task-based paradigms. Significant proportion of stroke survivors has permanent residual disability, indicating limited endogenous recovery capacity. In rat middle cerebral artery occlusion models (MCAo), CTX0E03 human neural stem cell (hNSCs) (clonally derived from human foetal cortical epithelium) injected to the striatum adjacent to the infarct 4 weeks after MCAo showed improvement in behavioural outcome measures along with histological evidence of increased host angiogenesis and neurogenesis.1 We examined the effects of intracerebral hNSC implantation in the putamen on functional networks assessed by longitudinal resting-state functional connectivity and explored associations with clinical measures. Patients for this study were from the Pilot Investigation of Stem Cells in Stroke (PISCES) trial2 a phase I, open-label study of intracerebral stereotactic implantation of CTX0E03 hNSCs to the ipsilateral putamen in patients with chronic ischaemic stroke. Eleven patients (National Institutes of Health Stroke Scale (NIHSS) ≥6, modified Rankin Scale (mRS)=2–4) with a first ischaemic stroke 6 months to 5 years previously were recruited. Cells were implanted under general anaesthesia and patients followed up over 2 years. Assessments covered neurological impairment (NIHSS), disability (mRS), spasticity (modified Ashworth scale) and activities of daily living (Barthel Index (BI)). Brain MRI was performed on three occasions, baseline (1 month prior), M1 (1 month after) and M12 (1 year after implantation) on a 3T GE Signa-Excite-HDxt scanner. Acquisition parameters included T1W (time to echo …

100 项与 ReNeuron Ltd. 相关的药物交易

登录后查看更多信息

100 项与 ReNeuron Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

3

1

临床2期

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Human retinal progenitor cells (ReNeuron Ltd.)	视网膜色素变性更多	临床2期
Exo-GF(ReNeuron)	-	临床前
Exo-miR(ReNeuron)	-	临床前
Exo-Cas(ReNeuron)	-	临床前
REN001	轻瘫更多	终止